Cognition Therapeutics (CGTX) News Today $0.58 -0.03 (-4.33%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$0.60 +0.02 (+2.71%) As of 02/21/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Cognition announces publication of zervimesine manufacturing processFebruary 20 at 6:05 PM | markets.businessinsider.comCognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead Alzheimer’s Candidate, Zervimesine (CT1812)February 20 at 8:03 AM | markets.businessinsider.comCognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Recommendation of "Buy" by BrokeragesFebruary 12, 2025 | americanbankingnews.comCognition Therapeutics price target raised to $2 from $1.50 at B. RileyFebruary 6, 2025 | markets.businessinsider.comCognition announces Phase 2 ‘SHIMMER’ study to be presented at ILBDCJanuary 30, 2025 | markets.businessinsider.comCognition's Positive Phase 2 ‘SHIMMER' Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDCJanuary 30, 2025 | globenewswire.comCognition Therapeutics CEO Participating in Longwood and Sachs ConferencesJanuary 8, 2025 | globenewswire.comB. Riley Securities Upgrades Cognition Therapeutics (CGTX)December 21, 2024 | msn.comCognition Therapeutics, Inc.: Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy BodiesDecember 19, 2024 | finanznachrichten.deThis Biotech Is Already Off To The Races Before The Opening BellDecember 18, 2024 | theglobeandmail.comCognition Therapeutics (NASDAQ:CGTX) Stock Quotes, Forecast and News SummaryDecember 18, 2024 | benzinga.comCognition Therapeutics announces results in Phase 2 study of CT1812December 18, 2024 | markets.businessinsider.comWhy Is Penny Stock Cognition Therapeutics Trading Over 93% On Wednesday?December 18, 2024 | benzinga.comCognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy BodiesDecember 18, 2024 | globenewswire.comWe're A Little Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn RateDecember 13, 2024 | finance.yahoo.comPositive Clinical Trial Developments and Financial Position Drive Buy Rating for Cognition TherapeuticsNovember 28, 2024 | markets.businessinsider.comCognition announces all participants completed final visit in SHIMMER studyNovember 26, 2024 | markets.businessinsider.comCognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy BodiesNovember 26, 2024 | globenewswire.comCognition Therapeutics provided an update on Phase 2 ‘SHINE’ study analysisNovember 25, 2024 | markets.businessinsider.comCognition Therapeutics’ Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer’s PopulationNovember 25, 2024 | markets.businessinsider.comCognition Therapeutics' Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer's PopulationNovember 25, 2024 | globenewswire.comCognition Therapeutics Reports Promising Q3 2024 ResultsNovember 14, 2024 | markets.businessinsider.comCognition Therapeutics, Inc.: Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical UpdateNovember 14, 2024 | finanznachrichten.deCognition Therapeutics sees cash runway into 2Q25November 14, 2024 | markets.businessinsider.comCognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical UpdateNovember 13, 2024 | globenewswire.comCognition Therapeutics to Present at Zacks SCR Life Sciences Investor ForumNovember 12, 2024 | globenewswire.comPositive Buy Rating Reaffirmed for Cognition Therapeutics Amid Promising Alzheimer’s Drug DataNovember 5, 2024 | markets.businessinsider.comCognition Therapeutics (CGTX) Gets a Buy from OppenheimerNovember 5, 2024 | markets.businessinsider.comNovember’s Small-Cap Treasures: 3 Stocks Poised for Growth (CGTX)Three promising small-cap stocks, poised for growth in healthcare, cybersecurity, and renewable energy, offer compelling investment opportunities for November.November 4, 2024 | marketbeat.comCognition Therapeutics’ Mixed Phase II Results Justify Hold Rating Amid Uncertain Broad EfficacyOctober 31, 2024 | markets.businessinsider.comCognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTADOctober 31, 2024 | globenewswire.comCognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTADOctober 29, 2024 | globenewswire.comAnalyses from Cognition's Positive Phase 2 ‘SHINE' Study of CT1812 in Mild-to-Moderate Alzheimer's Disease will be Presented in a Podium Presentation at CTADOctober 23, 2024 | globenewswire.comCognition Therapeutics releases new episode of ‘Conversations’ podcastOctober 23, 2024 | markets.businessinsider.comCognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)October 22, 2024 | globenewswire.comCognition Therapeutics Inc (CGTX) Q2 2024 Earnings Call Highlights: Promising Alzheimer's Trial ...October 9, 2024 | finance.yahoo.comCognition Therapeutics Will Participate in the Roth Healthcare Opportunities ConferenceOctober 2, 2024 | markets.businessinsider.comCognition Therapeutics Will Participate in the Roth Healthcare Opportunities ConferenceOctober 2, 2024 | globenewswire.comCognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common DementiaOctober 1, 2024 | globenewswire.comCognition Therapeutics (NASDAQ:CGTX) Stock, Insider Trading ActivitySeptember 26, 2024 | benzinga.comCognition Therapeutics (NASDAQ:CGTX) Stock, Short Interest ReportSeptember 25, 2024 | benzinga.comXBiotech Inc. (4XB.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comHealios K.K. (4593.T) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comFrost & Sullivan Grants the Global Cognitive Impairment Digital Therapy Innovation Award to BRAINAUSeptember 20, 2024 | markets.businessinsider.comGain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024September 19, 2024 | markets.businessinsider.comCognition Therapeutics to Participate in Upcoming September 2024 Investor ConferencesSeptember 3, 2024 | globenewswire.comCognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s DiseaseAugust 22, 2024 | markets.businessinsider.comCognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's DiseaseAugust 22, 2024 | globenewswire.comCognition Therapeutics, Inc. (NASDAQ:CGTX) Q1 2024 Earnings Call TranscriptAugust 12, 2024 | msn.comCognition Therapeutics, Inc. (CGTX) Q1 2024 Earnings Call TranscriptAugust 11, 2024 | seekingalpha.com Get Cognition Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address CGTX Media Mentions By Week CGTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CGTX News Sentiment▼0.000.60▲Average Medical News Sentiment CGTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CGTX Articles This Week▼22▲CGTX Articles Average Week Get Cognition Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Metagenomi News Today Elutia News Today Oramed Pharmaceuticals News Today MediciNova News Today Skye Bioscience News Today Tenaya Therapeutics News Today Cue Biopharma News Today Vor Biopharma News Today SELLAS Life Sciences Group News Today Adverum Biotechnologies News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CGTX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cognition Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CGTX Stock Alerts